Vampire bat thrombolytic study findings disappoint
Despite encouraging earlier results, themuch-awaited follow-up phase III DIAS-2trial on ischemic stroke patients treated withdesmoteplase afterthe onset of symptomsdid not showany improvement inclinical response at90 days.
Despite encouraging earlier results, the much-awaited follow-up phase III DIAS-2 trial on ischemic stroke patients treated with desmoteplase after the onset of symptoms did not show any improvement in clinical response at 90 days.
In previous investigational trials, the new drug, which is derived from vampire bat saliva, was shown to have a highly specific action and to be safe and effective over a longer treatment window than tissue plasminogen activator (tPA). Dr. Werner Hacke and colleagues at the University of Heidelberg in Germany assessed patients with acute stroke who were randomized within three hours of symptom onset to receive desmoteplase or placebo. There were no statistically significant differences in response rates between low/high dose of desmoteplase or placebo (47%/36% versus 46%).
Findings appeared in the February issue of The Lancet Neurology.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
